bromfenac ophthalmic solution / Generic mfg. - LARVOL DELTA

Cystoid Macular Edema after Light Adjustable Lens Adjustment - A Case Series (ARVO 2025) - "One case had recurrence and required cessation of the PGA and long term prolensa use, and one case is actively awaiting follow up...Layman Abstract (optional): Provide a 50-200 word description of your work that non-scientists can understand. Describe the big picture and the implications of your findings, not the study itself and the associated details."

Clinical • Cataract • Macular Edema • Ophthalmology • Retinal Disorders

ORBITAL MYOSITIS AS AN EXTRAINTESTINAL MANIFESTATION OF IBD (CCCongress 2025) - "Only five patients (45%) were on IBD medication at the time of diagnosis; three were on a biologic medication (infliximab, adalimumab, and ustekinumab), with the others on sulfasalazine and budesonide...One patient (9%) was treated with bromfenac ophthalmic solution...The number of patients in clinical remission for their IBD at the time of OM presentation may suggest a weaker correlation with underlying disease activity, in contrast to other EIMs. Additionally, the prevalence of cervical spinal disease among these patients, given their relatively younger age, warrants further investigation."

CNS Disorders • Crohn's disease • Dermatology • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammation • Inflammatory Bowel Disease • Myositis • Ocular Inflammation • Ophthalmology • Pain • Rheumatology • Ulcerative Colitis • Uveitis

Effects of Bromfenac on Macular Thickness After Phacoemulsification Surgery (clinicaltrials.gov) - P4 | N=87 | Completed | Sponsor: Inas Abd

New P4 trial • Cataract • Macular Edema • Ophthalmology

Assessing eFficacy and Safety of DEXTENZA 0.4 mg inseRt, Following Cataract Surgery (clinicaltrials.gov) - P4 | N=50 | Active, not recruiting | Sponsor: Nicole Fram M.D. | Recruiting ➔ Active, not recruiting | N=100 ➔ 50 | Trial completion date: Jun 2024 ➔ Apr 2025 | Trial primary completion date: Jun 2024 ➔ Apr 2025

Enrollment change • Enrollment closed • Surgery • Trial completion date • Trial primary completion date • Cataract • Inflammation • Macular Edema • Ocular Inflammation • Ophthalmology • Pain

Effect Of 0.09% Topical Bromfenac In Managing First Day Discomfort Following Photorefractive Keratectomy Compared To Our Up-Till-Now, Standard Technique (ESCRS 2023) - "Adjunct treatment with 0.09% bromfenac ophthalmic solution showed good efficacy for preventingearly postoperative pain following PRK. . It maybe considered as primary adjunct treatment to corticosteroids, as it improves dramatically patient comfort and adaptability to the procedure."

Ophthalmology

Assessing eFficacy and Safety of DEXTENZA 0.4 mg inseRt, Following Cataract Surgery (clinicaltrials.gov) - P4 | N=100 | Recruiting | Sponsor: Nicole Fram M.D. | Not yet recruiting ➔ Recruiting | Trial completion date: Mar 2024 ➔ Jun 2024 | Initiation date: Dec 2022 ➔ Jun 2023 | Trial primary completion date: Dec 2023 ➔ Jun 2024

Enrollment open • Surgery • Trial completion date • Trial initiation date • Trial primary completion date • Cataract • Inflammation • Macular Edema • Ocular Inflammation • Ophthalmology • Pain

A Study for Post op Inflammation After Cataract Surgery (clinicaltrials.gov) - P4 | N=40 | Enrolling by invitation | Sponsor: Wyse Eyecare | Trial completion date: May 2023 ➔ Dec 2023 | Trial primary completion date: Mar 2023 ➔ Oct 2023

Surgery • Trial completion date • Trial primary completion date • Cataract • Inflammation • Ophthalmology

Effect of 0.09% Topical Bromfenac in Preventing Macular Edema after Cataract Surgery (ASCRS-ASOA 2022) - "there were no cases of CME diagnosed in group A, while 8 cases in group B (6 cases with OCT identified ERM and 2 cases with DM, mean age 59 (42-75)), necessitating further management with dexamethasone and bromfenac for up to an additional 6 months and significant patient morbidity. Conclusion Adjunct treatment with 0.09% bromfenac ophthalmic solution showed good efficacy for preventing cystoid macular edema early after cataract surgery.It may be considered as primary adjunct treatment to corticosteroids following cataract surgery in younger and/or diabetic patients or when epiretinal membrane has been identified on OCT pre-operatively."

Cataract • Diabetes • Macular Edema • Metabolic Disorders • Ophthalmology • Retinal Disorders

Effect of 0.09% Topical Bromfenac in Managing Discomfort Following Photorefractive Keratectomy (ASCRS-ASOA 2022) - "All eyes received a bandage contact lens and topical moxifloxacin up to re-epitheliazation, dexamethasone sodium phosphate 0.1% chloramphenicol 0.5% over 4 weeks. The bromfenac group (121 cases) showed better pain management compared to the control group (134 cases) : mean score 1.5 to 3.2, 96 cases from group B required at least one dose of Lonarid and 75 an IM injection of paracetamole-none from group A. mean epitheliazation day was 3.5 vs. 3.6 and was not statistical significant between the 2 groups ConclusionAdjunct treatment with 0.09% bromfenac ophthalmic solution showed good efficacy for preventingearly postoperative pain following PRK. It maybe considered as primary adjunct treatment to corticosteroids, as it improves dramatically patient comfort and adaptability to the procedure."

Ophthalmology • Pain

EFFECT OF 0.09% TOPICAL BROMFENAC IN MANAGING DISCOMFORT FOLLOWING PHOTOREFRACTIVE KERATECTOMY (ESCRS-WM 2022) - "Adjunct treatment with 0.09% bromfenac ophthalmic solution showed good efficacy for preventingearly postoperative pain following PRK. . It maybe considered as primary adjunct treatment to corticosteroids, as it improves dramatically patient comfort and adaptability to the procedure."

Ophthalmology

PCME Prevention in Patients With NPDR (clinicaltrials.gov) - P4; N=90; Completed; Sponsor: Klinički Bolnički Centar Zagreb; Enrolling by invitation ➔ Completed

Clinical • Trial completion • Cataract • Macular Edema • Ophthalmology • IL6

One Week Sustained In Vivo Therapeutic Release and Safety of Novel Extended-Wear Silicone Hydrogel Contact Lenses. (PubMed, Adv Healthc Mater) - "Bromday (bromfenac ophthalmic solution, 0.09%, Bausch+Lomb) topical drops exhibit a quick peak concentration of 269.3 ± 85.7 µg mL and 100 min duration...Lenses are safe, well tolerated, and no corneal histological differences are observed. This work highlights the enormous potential of drug releasing lenses as a platform strategy, and offers a new dropless clinical strategy for post-cataract, uveitis, post-LASIK, and corneal abrasion treatment."

Journal • Preclinical • Cataract • Corneal Abrasion • Ocular Inflammation • Ophthalmology • Uveitis

PCME Prevention in Patients With NPDR (clinicaltrials.gov) - P4; N=90; Enrolling by invitation; Sponsor: Klinički Bolnički Centar Zagreb

Clinical • New P4 trial • Cataract • Macular Edema • Ophthalmology • IL6

Ocular Drug Delivery System-based on Solid Nanoparticles (PubMed, Yakugaku Zasshi) - "This review examines the usefulness of ophthalmic formulations based on solid nanoparticles, by using the specific example of indomethacin (IMC)...The solubility of IMC in IMC-NP dispersions was 4.18-fold higher than that in the suspensions containing IMC microparticles (IMC-MP suspensions), and IMC-NP dispersions were better tolerated than commercially available NSAIDs eye drops, such as IMC, pranoprofen, diclofenac, bromfenac, and nepafenac eyedrops, in human corneal epithelial cells. Moreover, the corneal penetration in IMC-NP dispersions was higher than that in commercially available IMC and IMC-MP suspensions, and three energy-dependent endocytosis pathways (clathrin-dependent endocytosis, caveolae-dependent endocytosis, and macropinocytosis) were related to the high ophthalmic bioavailability of IMC-NP dispersions. This information can be used to support future studies aimed at designing novel ophthalmic formulations."

Journal • Ocular Infections • Ophthalmology

Features of anti-inflammatory therapy of bacterial corneal ulcers (PubMed, Vestn Oftalmol) - "The use of a corticosteroid drug (Dexamethasone) for bacterial corneal ulcers reduces the duration of treatment and hospitalization and improves functional results of the treatment. Bromfenac 0.09% (Broxinac) was effective in the treatment of pain associated with bacterial corneal ulcer, but did not delay corneal epithelialization nor cause any corneal adverse events."

Journal • Keratitis • Ocular Infections • Ocular Inflammation • Ophthalmology • Pain

Efficacy and safety of sodium bromfenac eye drops in the treatment of postoperative inflammation in cataract surgery: A protocol for systematic review and meta-analysis. (PubMed, Medicine (Baltimore)) - "In this study, the efficacy and safety of sodium bromfenac eye drops in the treatment of postoperative inflammation of cataract surgery were evaluated by the effective rate, symptom score, adverse reactions, incidence, recurrence rate, etc. : This study will provide reliable evidence-based evidence for the clinical application of bromofenac sodium eye drops in the treatment of postoperative inflammation of cataract. DOI 10.17605/OSF.IO/3KP7R."

Journal • Retrospective data • Review • Cataract • Immunology • Inflammation • Ocular Inflammation • Ophthalmology • Pain

[VIRTUAL] TRENDS IN SEVERE ACUTE IDIOSYNCRATIC DRUG INDUCED LIVER INJURY: AN UPDATE FROM THE ALFSG REGISTRY (AASLD 2020) - "iDILI remains a leading cause of ALF and ALI in the US, with antimicrobials being the most frequently implicated drug class. Declining incidence of individual agents, e.g., NSAIDs and statins, may reflect drug withdrawal due to hepatotoxicity (bromfenac, cerivastatin) or evolving prescribing patterns (decreased phenytoin and INH usage). Regardless of causal agent, outcomes in iDILI ALF remain poor and emphasize the importance of early diagnosis and evaluation for emergency liver transplantation."

CNS Disorders • Hepatology • Liver Failure • Transplantation

[VIRTUAL] PO044: Ocular Pharmacokinetics and Clinical Outcomes of Once Daily and Twice Daily Dosing of Topical Bromfenac Sodium 0.09% After Phacoemulsification (AAO 2020) - "Conclusion Bromfenac achieves peak aqueous concentration after 2 hours with good ocular bioavailability after both OD and BD dosing. OD dosing is as efficacious as BD dosing in reducing inflammation."

Clinical • Clinical data • PK/PD data • Macular Edema • Ocular Inflammation • Ophthalmology

[VIRTUAL] RP30065773: Mini-PRK, Minimally Invasive, Rapid Recovery Epi-Bowman Blunt Keratectomy With Limited-Zone Epithelial Removal for Myopic PRK: One-Year Clinical Data of a Novel Technique (AAO 2020) - " Twenty patients (40 eyes) underwent mEBK-PRK for myopia with custom-shape and diameter, bromfenac 0.9 mg/mL the first postoperative day... These data suggest that mEBK-PRK may minimize pain and visual debilitation by accelerating re-epithelialization and early visual recovery. These data appear superior to those of LASIK and SMILE for the immediate postop rehabilitation and restrictions, similar in discomfort experienced with both of these lamellar procedures, with a potentially superior intraoperative safety profile."

Clinical data • Ophthalmology

The influence of topical non-steroidal anti-inflammatory drugs on the intraocular pressure lowering effect of topical prostaglandin analogues-A systemic review and meta-analysis. (PubMed, PLoS One) - "Results of our meta-analysis suggested that topical NSAIDs may enhance the IOP lowering effect of topical PGs in glaucoma patients."

Journal • Retrospective data • Review • Glaucoma • Ocular Inflammation • Ophthalmology

Economic evaluation of prevention of cystoid macular edema after cataract surgery in nondiabetic patients: ESCRS PREMED study report 4. (PubMed, J Cataract Refract Surg) - "In nondiabetic patients, combination treatment with topical bromfenac and dexamethasone was effective and cost-effective in preventing CME after cataract surgery, compared to treatment with either drug alone."

Clinical • HEOR • Journal • Cataract • Macular Edema • Metabolic Disorders • Ophthalmology

[VIRTUAL] Prostaglandin analog with β-blocker induce macular lesion in the intraocular lens (IOL): suturing eyes (EURETINA 2020) - "DuoTrav® was discontinued and brinzolamide , bromfenac and steroid were prescribed . IOL-suturing eyes may have the failure of the blood-aqueous and blood-reinal barrier and easily influenced by prostaglandin analog with β-blocker in the results of cystoid edema and macular hole."

Achromatopsia • Glaucoma • Hematological Disorders • Hypertension • Macular Edema • Mood Disorders • Ophthalmology • Retinal Disorders

[VIRTUAL] Mini-PRK: minimally invasive, rapid-recovery Epi-Bowman’s blunt keratectomy (EBK) with limited-zone epithelial removal for myopic PRK: One-year clinical data of a novel technique (ESCRS 2020) - "Bromfenac 0.9mg/ml was used through the first postoperative day... These data suggest that mini-PRK, may minimize postoperative discomfort and visual debilitation, accelerate re-epithelialization and early visual recovery, compared to traditional larger-epithelial zone PRK and even more-recent trans-epithelial (laser-epithelial removal)-PRK employed for myopic laser vision correction. These data appear superior to LASIK and Smile for the immediate postop rehabilitation and restrictions, similar in discomfort experienced with both of these lamellar procedures, with a potentially superior intra-operative safety profile."

Clinical data • Astigmatism • Ophthalmology

[VIRTUAL] The evaluation of farm therapy efficiency in postop routine cataract extraction (ESCRS 2020) - "1. In farmacological assistance for patients after routine cataract extraction the combination of steroid and non-stretoid antiflammatory drops should be used for antiflammatory effect potention. 2 The combination of steroid and non-steroid drops provides higher visual acuity, iop stability and prevents macular zone volume and widths increase."

Cataract • Macular Edema • Ophthalmology

[VIRTUAL] Effect modification of the prevention of cystoid macular edema after cataract surgery: a report from the ESCRS PREMED study (ESCRS 2020) - "Smoking appears to exert effect-modification on preventive treatment with the combination of both dexamethasone and bromfenac topically vs. bromfenac alone. This can be interpreted as a potential additional visual benefit for smokers treated with the combination approach, as compared to monotherapy with topical bromfenac."

Cataract • Macular Edema • Ophthalmology